Katja K. H. Aben

Katja K. H. Aben

Auto-generated profile, based on publicly available information

Katja K. H. Aben

Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Daniël Jonathan van der MeerDaniël Jonathan van der Meer
Daniël Jonathan van der Meer
HKHenrike Karim-Kos
Henrike Karim-Kos
MMMarianne van der Mark
Marianne van der Mark
KAKatja K. H. Aben
Katja K. H. Aben
Rhodé BijlsmaRhodé Bijlsma
Rhodé Bijlsma
Olga HussonOlga Husson
Olga Husson
Adolescent and young adult (AYA) cancer patients, aged 15–39 years at primary cancer diagnosis, form a distinct, understudied, and underserved group in cancer care. This study aimed to assess long-term trends in incidence, survival, and mortality of AYA cancer patients within the Netherlands. Data on all malignant AYA tumours diagnosed between 1990–2016 (n = 95,228) were obtained from the Netherlands Cancer Registry. European age-standardised incidence and mortality rates with average annual percentage change (AAPC) statistics and five-year relative survival rates were calculated. The overall cancer incidence increased from 54.6 to 70.3 per 100,000 person-years (AAPC: +1.37%) between 1990–2016, and increased for both sexes individually and for most cancer types. Five-year relative survival overall improved from 73.7% in 1990–1999 to 86.4% in 2010–2016 and improved for both sexes and most cancer types. Survival remained poor (<60%) for rhabdomyosarcoma, lung, stomach, liver, bladder, and pancreatic carcinomas, among others. Mortality rates among male AYAs overall declined from 10.8 to 6.6 (AAPC: −1.64%) and from 14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) for female AYAs since 1990. Mortality rates remained unchanged for male AYAs aged 20–24 and 25–29 years. In conclusion, over the past three decades, there has been a considerable increase in cancer incidence among AYAs in the Netherlands. Meanwhile, the survival improved and the mortality overall declined. Survival at five-years now well exceeds above 80%, but did not do so for all cancer types.

1 September 2020 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
RVR.W.M. Vernooij
R.W.M. Vernooij
RCR.G.H.M. Cremers
R.G.H.M. Cremers
HJH. Jansen
H. Jansen
DSD.M. Somford
D.M. Somford
LKL.A. Kiemeney
L.A. Kiemeney
KAK.K.H. Aben
K.K.H. Aben

1 January 2022 in Clinical Nutrition
Verified
Journal Article
Open access
JMJake S.F. Maurits
Jake S.F. Maurits
JSJ.P. Michiel Sedelaar
J.P. Michiel Sedelaar
PMPeter F.A. Mulders
Peter F.A. Mulders
KAKatja K.H. Aben
Katja K.H. Aben
LKLambertus A.L.M. Kiemeney
Lambertus A.L.M. Kiemeney
Alina VrielingAlina Vrieling
Alina Vrieling
Body composition has been associated with disease outcome in several cancer types. Results for localized and metastatic renal cell cancer (RCC) are limited and inconsistent. Our aim was to examine the association between body composition and survival in RCC. We conducted a population-based historical cohort study including patients diagnosed with RCC from 2008 to 2012. Diagnostic Computed Tomography images at the third lumbar vertebra (L3) were assessed for skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI). Clinical data was retrieved from medical records. Multivariable Cox regressions with restricted cubic splines were used to determine hazard ratios (HRs) and 95% confidence intervals (95%CIs) for 10-unit increases in body composition features with overall survival (OS) and recurrence-free survival (RFS). We included 719 stage I-III (of whom 254 (35.3%) died and 148 (21.9%) experienced recurrence) and 320 stage IV RCC patients (of whom 298 (93.1%) died). Median follow-up was 6.35 years (interquartile range; 1.41-8.23). For stage I-III, higher SMD was associated with better OS (men: HR 0.86; 95% CI 0.68-1.08; women: HR 0.69; 95% CI 0.50-0.95). Lower compared to median VATI was associated with worse OS for both men (HR 1.38; 95%CI 1.05-1.83 for VATI = 25) and women (HR 1.67; 95%CI 1.01-2.78 for VATI = 20). For stage IV, higher SMD and higher VATI were associated with better OS among men (HR 0.74; 95% CI 0.59-0.94 and HR 0.93; 95% CI 0.88-0.99, respectively). Results for women were similar but non-significant. No statistically significant associations were found for SMI or SATI. Higher SMD and higher VATI were marginally associated with better survival in RCC patients and might be useful for better prognostication. However, the added value to current prognostic scores needs to be investigated.

1 March 2019 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
RVRobin W. M. Vernooij
Robin W. M. Vernooij
IOInge van Oort
Inge van Oort
TRTheo M. de Reijke
Theo M. de Reijke
KAKatja K.H. Aben
Katja K.H. Aben

25 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAnne J. Grotenhuis
Anne J. Grotenhuis
ADAleksandra M. Dudek
Aleksandra M. Dudek
GVGerald Verhaegh
Gerald Verhaegh
JWJ. Alfred Witjes
J. Alfred Witjes
KAKatja K. Aben
Katja K. Aben
LKLambertus A. Kiemeney
Lambertus A. Kiemeney
In the last few years, susceptibility loci have been identified for urinary bladder cancer (UBC) through candidate-gene and genome-wide association studies. Prognostic relevance of most of these loci is yet unknown. In this study, we used data of the Nijmegen Bladder Cancer Study (NBCS) to perform a comprehensive evaluation of the prognostic relevance of all confirmed UBC susceptibility loci. Detailed clinical data concerning diagnosis, stage, treatment, and disease course of a population-based series of 1,602 UBC patients were collected retrospectively based on a medical file survey. Kaplan-Meier survival analyses and Cox proportional hazard regression were performed, and log-rank tests calculated, to evaluate the association between 12 confirmed UBC susceptibility variants and recurrence and progression in non-muscle invasive bladder cancer (NMIBC) patients. Among muscle-invasive or metastatic bladder cancer (MIBC) patients, association of these variants with overall survival was tested. Subgroup analyses by tumor aggressiveness and smoking status were performed in NMIBC patients. In the overall NMIBC group (n = 1,269), a statistically significant association between rs9642880 at 8q24 and risk of progression was observed (GT vs. TT: HR = 1.08 (95% CI: 0.76–1.54), GG vs. TT: HR = 1.81 (95% CI: 1.23–2.66), P for trend = 2.6×10−3). In subgroup analyses, several other variants showed suggestive, though non-significant, prognostic relevance for recurrence and progression in NMIBC and survival in MIBC. This study provides suggestive evidence that genetic loci involved in UBC etiology may influence disease prognosis. Elucidation of the causal variant(s) could further our understanding of the mechanism of disease, could point to new therapeutic targets, and might aid in improvement of prognostic tools.

1 November 2019 in European Journal of Cancer
Verified
Journal Article
Open access
JWJ.E.W. Walraven
J.E.W. Walraven
IDI.M.E. Desar
I.M.E. Desar
JDJ.J.M. Hoeven van der
J.J.M. Hoeven van der
KAK.K.H. Aben
K.K.H. Aben
RVR. Hillegersberg van
R. Hillegersberg van
RVR.H.A. Verhoeven
R.H.A. Verhoeven
For optimal oncological care, it is recommended to discuss every patient with cancer in a multidisciplinary team meeting (MDTM). This is a time consuming and expensive practice, leading to a growing demand to change the current workflow. We aimed to investigate the number of patients discussed in MDTMs and to identify characteristics associated with not being discussed. Data of patients with a newly diagnosed solid malignant tumour in 2015 and 2016 were analysed through the nationwide population-based Netherlands Cancer Registry (NCR). We clustered tumour types in groups that were frequently discussed within a tumour-specific MDTM. Tumour types without information about MDTMs in the NCR were excluded. Multivariable logistic regression analyses were used to analyse factors associated with not being discussed. Out of 105.305 patients with cancer, 91% were discussed in a MDTM, varying from 74% to 99% between the different tumour groups. Significantly less frequently discussed were patients aged ≥75 years (odds ratio [OR] = 0.7, 95% confidence interval [CI] = 0.6-0.7), patients diagnosed with disease stage I (OR = 0.5, 95% CI = 0.5-0.6), IV (OR = 0.4, 95% CI = 0.4-0.4) or unknown (OR = 0.2, 95% CI = 0.2-0.2) and patients who received no treatment (OR = 0.3, 95% CI = 0.3-0.3). Patients who received a multidisciplinary treatment were more likely to be discussed in contrary to a monodisciplinary treatment (OR = 4.6, 95% CI = 4.2-5.1). In general, most patients with cancer were actually discussed in a MDTM, although differences were observed between tumour groups. Factors associated with not being discussed may, at least partially, reflect the absence of a multidisciplinary question. These results form a starting point for debate on a more durable and efficient new MDTM strategy.